FDA Advisory Committee Discusses Clinical Data Package for BioMarin's Kyndrisa for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

By: via Benzinga
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Peripheral and Central Nervous System Drugs Advisory Committee of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.